- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02997228
Kombinationskemoterapi, Bevacizumab och/eller Atezolizumab vid behandling av patienter med bristfällig DNA-felmatchning Reparation Metastatisk kolorektal cancer, COMMIT-studien
Kolorektalcancer Metastatisk dMMR/MSI-H Immuno-Therapy (COMMIT) Studie: En randomiserad fas III-studie av mFOLFOX6/Bevacizumab/Atezolizumab-kombination kontra singelmedel atezolizumab i första linjens behandling av patienter med bristfällig DNA-felanpassningsreparation (dMMR) Instabilitet-Hög (MSI-H) Metastaserande kolorektal cancer
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Studieöversikt
Status
Intervention / Behandling
- Övrig: Quality-of-Life Assessment
- Biologisk: Bevacizumab
- Läkemedel: Fluorouracil
- Procedur: Magnetic Resonance Imaging
- Övrig: Questionnaire Administration
- Procedur: Biospecimen Collection
- Läkemedel: Atezolizumab
- Läkemedel: Oxaliplatin
- Procedur: Computed Tomography
- Läkemedel: Leucovorin
- Procedur: Positron Emission Tomography
Detaljerad beskrivning
PRIMARY OBJECTIVE:
I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (modified [m]FOLFOX6)/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab.
SECONDARY OBJECTIVES:
I. To compare the overall survival. II. To compare the objective response rates (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
III. To determine the safety profiles of single agent atezolizumab and the combination of mFOLFOX6/bevacizumab/atezolizumab in patients with mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
IV. To determine the duration of response. V. To determine the duration of stable disease. VI. To determine the rate of progression-free survival (PFS) at 12 months. VII. To evaluate the disease control rate (complete response [CR] + partial response [PR] + stable disease [SD]) at 12 months.
TRANSLATIONAL OBJECTIVE:
I. To bank tissue and blood samples for other future correlative studies from patients enrolled on the study.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I (CLOSED TO ACCRUAL 6/4/2020): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with or without positron emission tomography (PET) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM II: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8 weeks for 18 months, and then every 12 weeks for up to 5 years.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
Arizona
-
Kingman, Arizona, Förenta staterna, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, Förenta staterna, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
Anaheim, California, Förenta staterna, 92806
- Kaiser Permanente-Anaheim
-
Baldwin Park, California, Förenta staterna, 91706
- Kaiser Permanente-Baldwin Park
-
Bellflower, California, Förenta staterna, 90706
- Kaiser Permanente-Bellflower
-
Berkeley, California, Förenta staterna, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Concord, California, Förenta staterna, 94520
- John Muir Medical Center-Concord
-
Fontana, California, Förenta staterna, 92335
- Kaiser Permanente-Fontana
-
Harbor City, California, Förenta staterna, 90710
- Kaiser Permanente South Bay
-
Irvine, California, Förenta staterna, 92618
- Kaiser Permanente-Irvine
-
Los Angeles, California, Förenta staterna, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Förenta staterna, 90034
- Kaiser Permanente West Los Angeles
-
Marysville, California, Förenta staterna, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Förenta staterna, 95355
- Memorial Medical Center
-
Ontario, California, Förenta staterna, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Förenta staterna, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Förenta staterna, 92868
- Saint Joseph Hospital - Orange
-
Panorama City, California, Förenta staterna, 91402
- Kaiser Permanente - Panorama City
-
Riverside, California, Förenta staterna, 92505
- Kaiser Permanente-Riverside
-
Sacramento, California, Förenta staterna, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Förenta staterna, 95817
- University of California Davis Comprehensive Cancer Center
-
Salinas, California, Förenta staterna, 93901
- Salinas Valley Memorial
-
San Diego, California, Förenta staterna, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Förenta staterna, 92108
- Kaiser Permanente-Rio San Diego
-
San Marcos, California, Förenta staterna, 92078
- Kaiser Permanente-San Marcos
-
Walnut Creek, California, Förenta staterna, 94598
- John Muir Medical Center-Walnut Creek
-
Whittier, California, Förenta staterna, 90602
- Presbyterian Intercommunity Hospital
-
Woodland Hills, California, Förenta staterna, 91367
- Kaiser Permanente-Woodland Hills
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Förenta staterna, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Förenta staterna, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Förenta staterna, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Förenta staterna, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Förenta staterna, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Förenta staterna, 80920
- Memorial Hospital North
-
Denver, Colorado, Förenta staterna, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Förenta staterna, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Förenta staterna, 80204
- Denver Health Medical Center
-
Denver, Colorado, Förenta staterna, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Förenta staterna, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, Förenta staterna, 80210
- AdventHealth Porter
-
Englewood, Colorado, Förenta staterna, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Förenta staterna, 80113
- Swedish Medical Center
-
Fort Collins, Colorado, Förenta staterna, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Förenta staterna, 80528
- Cancer Care and Hematology-Fort Collins
-
Golden, Colorado, Förenta staterna, 80401
- National Jewish Health-Western Hematology Oncology
-
Greeley, Colorado, Förenta staterna, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Förenta staterna, 80631
- Banner North Colorado Medical Center
-
Littleton, Colorado, Förenta staterna, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Förenta staterna, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Förenta staterna, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Förenta staterna, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton, Colorado, Förenta staterna, 80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge, Colorado, Förenta staterna, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Danbury, Connecticut, Förenta staterna, 06810
- Danbury Hospital
-
Hartford, Connecticut, Förenta staterna, 06102
- Hartford Hospital
-
Meriden, Connecticut, Förenta staterna, 06451
- Midstate Medical Center
-
New Britain, Connecticut, Förenta staterna, 06050
- The Hospital of Central Connecticut
-
Norwich, Connecticut, Förenta staterna, 06360
- William Backus Hospital
-
-
Delaware
-
Millville, Delaware, Förenta staterna, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Förenta staterna, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Förenta staterna, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Förenta staterna, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20002
- Kaiser Permanente-Capitol Hill Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, Förenta staterna, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Förenta staterna, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Gainesville, Florida, Förenta staterna, 32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville, Florida, Förenta staterna, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Förenta staterna, 32803
- AdventHealth Orlando
-
-
Georgia
-
Albany, Georgia, Förenta staterna, 31701
- Phoebe Putney Memorial Hospital
-
Athens, Georgia, Förenta staterna, 30607
- University Cancer and Blood Center LLC
-
Augusta, Georgia, Förenta staterna, 30912
- Augusta University Medical Center
-
Augusta, Georgia, Förenta staterna, 30901
- Augusta Oncology Associates PC-D'Antignac
-
Augusta, Georgia, Förenta staterna, 30909
- Augusta Oncology Associates PC-Wheeler
-
Newnan, Georgia, Förenta staterna, 30265
- CTCA at Southeastern Regional Medical Center
-
-
Idaho
-
Boise, Idaho, Förenta staterna, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Förenta staterna, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Förenta staterna, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Förenta staterna, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Förenta staterna, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Förenta staterna, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Förenta staterna, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Förenta staterna, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Förenta staterna, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Förenta staterna, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Förenta staterna, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Förenta staterna, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Förenta staterna, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Förenta staterna, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Förenta staterna, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Förenta staterna, 60612
- University of Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Förenta staterna, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Förenta staterna, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Förenta staterna, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Förenta staterna, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Förenta staterna, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Förenta staterna, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Förenta staterna, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Förenta staterna, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, Förenta staterna, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Förenta staterna, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Förenta staterna, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Förenta staterna, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Förenta staterna, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Förenta staterna, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, Förenta staterna, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Förenta staterna, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Förenta staterna, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Förenta staterna, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Förenta staterna, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Förenta staterna, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Förenta staterna, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Förenta staterna, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Förenta staterna, 62702
- Springfield Clinic
-
Urbana, Illinois, Förenta staterna, 61801
- Carle Cancer Center
-
Washington, Illinois, Förenta staterna, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46237
- Franciscan Health Indianapolis
-
Indianapolis, Indiana, Förenta staterna, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Förenta staterna, 46219
- Community Cancer Center East
-
Indianapolis, Indiana, Förenta staterna, 46227
- Community Cancer Center South
-
Indianapolis, Indiana, Förenta staterna, 46256
- Community Cancer Center North
-
Kokomo, Indiana, Förenta staterna, 46904
- Community Howard Regional Health
-
Lafayette, Indiana, Förenta staterna, 47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Michigan City, Indiana, Förenta staterna, 46360
- Woodland Cancer Care Center
-
Mooresville, Indiana, Förenta staterna, 46158
- Franciscan Health Mooresville
-
Terre Haute, Indiana, Förenta staterna, 47804
- Union Hospital
-
-
Iowa
-
Ames, Iowa, Förenta staterna, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Förenta staterna, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Förenta staterna, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Boone, Iowa, Förenta staterna, 50036
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, Förenta staterna, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Förenta staterna, 52403
- Oncology Associates at Mercy Medical Center
-
Clive, Iowa, Förenta staterna, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Förenta staterna, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Förenta staterna, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Förenta staterna, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Förenta staterna, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Förenta staterna, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Förenta staterna, 50501
- McFarland Clinic - Trinity Cancer Center
-
Fort Dodge, Iowa, Förenta staterna, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Förenta staterna, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, Förenta staterna, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Förenta staterna, 50158
- McFarland Clinic - Marshalltown
-
West Des Moines, Iowa, Förenta staterna, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays, Kansas, Förenta staterna, 67601
- HaysMed
-
Lawrence, Kansas, Förenta staterna, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Förenta staterna, 66061
- The University of Kansas Cancer Center - Olathe
-
Salina, Kansas, Förenta staterna, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Förenta staterna, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, Förenta staterna, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, Förenta staterna, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Förenta staterna, 67214
- Cancer Center of Kansas - Wichita
-
-
Kentucky
-
Bardstown, Kentucky, Förenta staterna, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Lexington, Kentucky, Förenta staterna, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Förenta staterna, 40503
- Baptist Health Lexington
-
Lexington, Kentucky, Förenta staterna, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Louisville, Kentucky, Förenta staterna, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, Förenta staterna, 40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville, Kentucky, Förenta staterna, 40217
- Norton Audubon Hospital and Medical Campus
-
-
Louisiana
-
Kenner, Louisiana, Förenta staterna, 70065
- Ochsner Medical Center Kenner
-
New Orleans, Louisiana, Förenta staterna, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Augusta, Maine, Förenta staterna, 04330
- Harold Alfond Center for Cancer Care
-
Bangor, Maine, Förenta staterna, 04401
- Eastern Maine Medical Center
-
Belfast, Maine, Förenta staterna, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Förenta staterna, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, Förenta staterna, 04412
- Lafayette Family Cancer Center-EMMC
-
Rockport, Maine, Förenta staterna, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Förenta staterna, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
South Portland, Maine, Förenta staterna, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21244
- Kaiser Permanente-Woodlawn Medical Center
-
Easton, Maryland, Förenta staterna, 21601
- University of Maryland Shore Medical Center at Easton
-
Gaithersburg, Maryland, Förenta staterna, 20879
- Kaiser Permanente-Gaithersburg Medical Center
-
Largo, Maryland, Förenta staterna, 20774
- Kaiser Permanente - Largo Medical Center
-
Lutherville, Maryland, Förenta staterna, 21093
- Kaiser Permanente Lutherville - Timonium Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Dana-Farber Cancer Institute
-
Lowell, Massachusetts, Förenta staterna, 01854
- Lowell General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Bay City, Michigan, Förenta staterna, 48706
- McLaren Cancer Institute-Bay City
-
Bloomfield, Michigan, Förenta staterna, 48302
- McLaren Cancer Institute-Bloomfield
-
Brighton, Michigan, Förenta staterna, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Förenta staterna, 48114
- Trinity Health Medical Center - Brighton
-
Brownstown, Michigan, Förenta staterna, 48183
- Henry Ford Cancer Institute-Downriver
-
Canton, Michigan, Förenta staterna, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Förenta staterna, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Förenta staterna, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Förenta staterna, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Förenta staterna, 48346
- McLaren Cancer Institute-Clarkston
-
Clarkston, Michigan, Förenta staterna, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Förenta staterna, 48346
- Newland Medical Associates-Clarkston
-
Clinton Township, Michigan, Förenta staterna, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Förenta staterna, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Förenta staterna, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Förenta staterna, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Förenta staterna, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Förenta staterna, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, Förenta staterna, 48532
- Singh and Arora Hematology Oncology PC
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Jackson, Michigan, Förenta staterna, 49201
- Allegiance Health
-
Kalamazoo, Michigan, Förenta staterna, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, Förenta staterna, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, Förenta staterna, 48912
- University of Michigan Health - Sparrow Lansing
-
Lapeer, Michigan, Förenta staterna, 48446
- McLaren Cancer Institute-Lapeer Region
-
Livonia, Michigan, Förenta staterna, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Förenta staterna, 48154
- Hope Cancer Clinic
-
Mount Clemens, Michigan, Förenta staterna, 48043
- McLaren Cancer Institute-Macomb
-
Mount Pleasant, Michigan, Förenta staterna, 48858
- McLaren Cancer Institute-Central Michigan
-
Novi, Michigan, Förenta staterna, 48377
- Henry Ford Medical Center-Columbus
-
Petoskey, Michigan, Förenta staterna, 49770
- McLaren Cancer Institute-Northern Michigan
-
Pontiac, Michigan, Förenta staterna, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Förenta staterna, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Port Huron, Michigan, Förenta staterna, 48060
- McLaren-Port Huron
-
Saginaw, Michigan, Förenta staterna, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Förenta staterna, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Förenta staterna, 48764
- MyMichigan Medical Center Tawas
-
Traverse City, Michigan, Förenta staterna, 49684
- Munson Medical Center
-
West Bloomfield, Michigan, Förenta staterna, 48322
- Henry Ford West Bloomfield Hospital
-
West Branch, Michigan, Förenta staterna, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Förenta staterna, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Förenta staterna, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Förenta staterna, 55337
- Minnesota Oncology - Burnsville
-
Deer River, Minnesota, Förenta staterna, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Förenta staterna, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Förenta staterna, 55746
- Essentia Health Hibbing Clinic
-
Maplewood, Minnesota, Förenta staterna, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Förenta staterna, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Förenta staterna, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Förenta staterna, 55454
- Health Partners Inc
-
Saint Paul, Minnesota, Förenta staterna, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Förenta staterna, 55102
- United Hospital
-
Sandstone, Minnesota, Förenta staterna, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Förenta staterna, 55792
- Essentia Health Virginia Clinic
-
-
Mississippi
-
Grenada, Mississippi, Förenta staterna, 38901
- Baptist Cancer Center-Grenada
-
New Albany, Mississippi, Förenta staterna, 38652
- Baptist Memorial Hospital and Cancer Center-Union County
-
Oxford, Mississippi, Förenta staterna, 38655
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Southhaven, Mississippi, Förenta staterna, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Ballwin, Missouri, Förenta staterna, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Cape Girardeau, Missouri, Förenta staterna, 63703
- Saint Francis Medical Center
-
Columbia, Missouri, Förenta staterna, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Joplin, Missouri, Förenta staterna, 64804
- Freeman Health System
-
Joplin, Missouri, Förenta staterna, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Förenta staterna, 64108
- University Health Truman Medical Center
-
St Louis, Missouri, Förenta staterna, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Förenta staterna, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda, Montana, Förenta staterna, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Förenta staterna, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Förenta staterna, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Förenta staterna, 59405
- Great Falls Clinic
-
Great Falls, Montana, Förenta staterna, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Förenta staterna, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Förenta staterna, 59901
- Logan Health Medical Center
-
Missoula, Montana, Förenta staterna, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Förenta staterna, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Förenta staterna, 89183
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Förenta staterna, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Förenta staterna, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Manchester, New Hampshire, Förenta staterna, 03104
- Dartmouth Cancer Center - Manchester/ DCC Manchester
-
Nashua, New Hampshire, Förenta staterna, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Hamilton, New Jersey, Förenta staterna, 08690
- The Cancer Institute of New Jersey Hamilton
-
Morristown, New Jersey, Förenta staterna, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rutgers Cancer Institute of New Jersey
-
Paramus, New Jersey, Förenta staterna, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, Förenta staterna, 07450
- Valley Health System Ridgewood Campus
-
Somerville, New Jersey, Förenta staterna, 08876
- Robert Wood Johnson University Hospital Somerset
-
Summit, New Jersey, Förenta staterna, 07902
- Overlook Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87106
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, Förenta staterna, 87110
- Presbyterian Kaseman Hospital
-
Las Cruces, New Mexico, Förenta staterna, 88011
- Memorial Medical Center-Las Cruces
-
Rio Rancho, New Mexico, Förenta staterna, 87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Buffalo, New York, Förenta staterna, 14263
- Roswell Park Cancer Institute
-
Elmira, New York, Förenta staterna, 14905
- Arnot Ogden Medical Center/Falck Cancer Center
-
Lake Success, New York, Förenta staterna, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Förenta staterna, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Förenta staterna, 14642
- University of Rochester
-
White Plains, New York, Förenta staterna, 10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Clinton, North Carolina, Förenta staterna, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Förenta staterna, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Förenta staterna, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, Förenta staterna, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Kenansville, North Carolina, Förenta staterna, 28349
- ECU Health Oncology Kenansville
-
Kinston, North Carolina, Förenta staterna, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Förenta staterna, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Richlands, North Carolina, Förenta staterna, 28574
- ECU Health Oncology Richlands
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Förenta staterna, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Förenta staterna, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Förenta staterna, 58122
- Sanford Broadway Medical Center
-
Grand Forks, North Dakota, Förenta staterna, 58201
- Altru Cancer Center
-
-
Ohio
-
Akron, Ohio, Förenta staterna, 44307
- Cleveland Clinic Akron General
-
Belpre, Ohio, Förenta staterna, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, Förenta staterna, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Förenta staterna, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chillicothe, Ohio, Förenta staterna, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Förenta staterna, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Förenta staterna, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Förenta staterna, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Förenta staterna, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Förenta staterna, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Förenta staterna, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Förenta staterna, 43228
- Doctors Hospital
-
Columbus, Ohio, Förenta staterna, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, Förenta staterna, 43215
- Grant Medical Center
-
Columbus, Ohio, Förenta staterna, 43222
- Mount Carmel Health Center West
-
Dayton, Ohio, Förenta staterna, 45409
- Miami Valley Hospital
-
Delaware, Ohio, Förenta staterna, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Förenta staterna, 43015
- Grady Memorial Hospital
-
Kettering, Ohio, Förenta staterna, 45409
- Greater Dayton Cancer Center
-
Lancaster, Ohio, Förenta staterna, 43130
- Fairfield Medical Center
-
Mansfield, Ohio, Förenta staterna, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Mansfield, Ohio, Förenta staterna, 44903
- OhioHealth Mansfield Hospital
-
Marietta, Ohio, Förenta staterna, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Förenta staterna, 43302
- OhioHealth Marion General Hospital
-
Mayfield Heights, Ohio, Förenta staterna, 44124
- Hillcrest Hospital Cancer Center
-
Mount Vernon, Ohio, Förenta staterna, 43050
- Knox Community Hospital
-
Newark, Ohio, Förenta staterna, 43055
- Licking Memorial Hospital
-
Portsmouth, Ohio, Förenta staterna, 45662
- Southern Ohio Medical Center
-
Sandusky, Ohio, Förenta staterna, 44870
- North Coast Cancer Care
-
Sylvania, Ohio, Förenta staterna, 43560
- ProMedica Flower Hospital
-
Warrensville Heights, Ohio, Förenta staterna, 44122
- South Pointe Hospital
-
West Chester, Ohio, Förenta staterna, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westerville, Ohio, Förenta staterna, 43081
- Saint Ann's Hospital
-
Zanesville, Ohio, Förenta staterna, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton, Oklahoma, Förenta staterna, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Förenta staterna, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
Tulsa, Oklahoma, Förenta staterna, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Bend, Oregon, Förenta staterna, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Förenta staterna, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Förenta staterna, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Förenta staterna, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Förenta staterna, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Förenta staterna, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Förenta staterna, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Förenta staterna, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Förenta staterna, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, Förenta staterna, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Förenta staterna, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem, Pennsylvania, Förenta staterna, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Easton, Pennsylvania, Förenta staterna, 18045
- Saint Luke's Hospital-Anderson Campus
-
Erie, Pennsylvania, Förenta staterna, 16544
- Saint Vincent Hospital
-
Harrisburg, Pennsylvania, Förenta staterna, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Jefferson Hills, Pennsylvania, Förenta staterna, 15025
- Jefferson Hospital
-
Monroeville, Pennsylvania, Förenta staterna, 15146
- Forbes Hospital
-
Natrona Heights, Pennsylvania, Förenta staterna, 15065
- Allegheny Valley Hospital
-
Pittsburgh, Pennsylvania, Förenta staterna, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- UPMC Hillman Cancer Center
-
Quakertown, Pennsylvania, Förenta staterna, 18951
- Saint Luke's Hospital-Quakertown Campus
-
West Reading, Pennsylvania, Förenta staterna, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Förenta staterna, 15090
- Wexford Health and Wellness Pavilion
-
Willow Grove, Pennsylvania, Förenta staterna, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Anderson, South Carolina, Förenta staterna, 29621
- AnMed Health Cancer Center
-
Beaufort, South Carolina, Förenta staterna, 29902
- Beaufort Memorial Hospital
-
Boiling Springs, South Carolina, Förenta staterna, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Förenta staterna, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Förenta staterna, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Förenta staterna, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Förenta staterna, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Förenta staterna, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Förenta staterna, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Förenta staterna, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Förenta staterna, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Förenta staterna, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Aberdeen, South Dakota, Förenta staterna, 57401
- Avera Cancer Institute-Aberdeen
-
Sioux Falls, South Dakota, Förenta staterna, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Förenta staterna, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Förenta staterna, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Bristol, Tennessee, Förenta staterna, 37620
- Bristol Regional Medical Center
-
Collierville, Tennessee, Förenta staterna, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Cookeville, Tennessee, Förenta staterna, 38501
- Cookeville Regional Medical Center
-
Johnson City, Tennessee, Förenta staterna, 37604
- Wellmont Medical Associates Oncology and Hematology-Johnson City
-
Kingsport, Tennessee, Förenta staterna, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Förenta staterna, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Memphis, Tennessee, Förenta staterna, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Amarillo, Texas, Förenta staterna, 79106
- The Don and Sybil Harrington Cancer Center
-
Beaumont, Texas, Förenta staterna, 77701
- Baptist Hospitals of Southeast Texas Cancer Center
-
Conroe, Texas, Förenta staterna, 77384
- UT MD Anderson - The Woodlands
-
Dallas, Texas, Förenta staterna, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Förenta staterna, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Edinburg, Texas, Förenta staterna, 78539
- STCC at DHR Health Institute for Research and Development
-
Houston, Texas, Förenta staterna, 77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston, Texas, Förenta staterna, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Förenta staterna, 77030
- Houston Methodist Hospital
-
Houston, Texas, Förenta staterna, 77079
- UT MD Anderson - West Houston
-
League City, Texas, Förenta staterna, 77573
- UT MD Anderson - League City
-
Port Arthur, Texas, Förenta staterna, 77642
- Baptist Regional Cancer Network-Cancer Center of Southeast Texas
-
Sugar Land, Texas, Förenta staterna, 77478
- UT MD Anderson - Sugar Land
-
Temple, Texas, Förenta staterna, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Saint Johnsbury, Vermont, Förenta staterna, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Bristol, Virginia, Förenta staterna, 24201
- Ballad Health Cancer Care - Bristol
-
Burke, Virginia, Förenta staterna, 22015
- Kaiser Permanente-Burke Medical Center
-
Fishersville, Virginia, Förenta staterna, 22939
- Augusta Health Center for Cancer and Blood Disorders
-
Lynchburg, Virginia, Förenta staterna, 24501
- Centra Alan B Pearson Regional Cancer Center
-
McLean, Virginia, Förenta staterna, 22102
- Kaiser Permanente Tysons Corner Medical Center
-
Norton, Virginia, Förenta staterna, 24273
- Ballad Health Cancer Care - Norton
-
Richmond, Virginia, Förenta staterna, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Förenta staterna, 23229
- Virginia Cancer Institute
-
Richmond, Virginia, Förenta staterna, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Förenta staterna, 23970
- VCU Community Memorial Health Center
-
Woodbridge, Virginia, Förenta staterna, 22192
- Kaiser Permanente-Caton Hill Medical Center
-
-
Washington
-
Edmonds, Washington, Förenta staterna, 98026
- Swedish Cancer Institute-Edmonds
-
Issaquah, Washington, Förenta staterna, 98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend, Washington, Förenta staterna, 98368
- Jefferson Healthcare
-
Seattle, Washington, Förenta staterna, 98122
- Swedish Medical Center-First Hill
-
Spokane, Washington, Förenta staterna, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, Förenta staterna, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
-
West Virginia
-
Charleston, West Virginia, Förenta staterna, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, Förenta staterna, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Förenta staterna, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Antigo, Wisconsin, Förenta staterna, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Appleton, Wisconsin, Förenta staterna, 54911
- ThedaCare Regional Cancer Center
-
Appleton, Wisconsin, Förenta staterna, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Ashland, Wisconsin, Förenta staterna, 54806
- Duluth Clinic Ashland
-
Brookfield, Wisconsin, Förenta staterna, 53045
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
-
Eau Claire, Wisconsin, Förenta staterna, 54701
- Marshfield Medical Center-EC Cancer Center
-
Franklin, Wisconsin, Förenta staterna, 53132
- Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
-
Green Bay, Wisconsin, Förenta staterna, 54301
- Bellin Memorial Hospital
-
Janesville, Wisconsin, Förenta staterna, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Johnson Creek, Wisconsin, Förenta staterna, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
La Crosse, Wisconsin, Förenta staterna, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Förenta staterna, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Förenta staterna, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Förenta staterna, 54449
- Marshfield Medical Center-Marshfield
-
Medford, Wisconsin, Förenta staterna, 54451
- Aspirus Medford Hospital
-
Minocqua, Wisconsin, Förenta staterna, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Förenta staterna, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Förenta staterna, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Förenta staterna, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Förenta staterna, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, Förenta staterna, 53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rhinelander, Wisconsin, Förenta staterna, 54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Rice Lake, Wisconsin, Förenta staterna, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Förenta staterna, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Förenta staterna, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Förenta staterna, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Förenta staterna, 54401
- Aspirus Cancer Care-Wausau
-
Wauwatosa, Wisconsin, Förenta staterna, 53226
- Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
-
Weston, Wisconsin, Förenta staterna, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Förenta staterna, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Wyoming
-
Cheyenne, Wyoming, Förenta staterna, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Förenta staterna, 82414
- Billings Clinic-Cody
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
-
Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), either with or without bevacizumab prior to enrollment. Upon enrollment, the preceding single cycle of FOLFOX or FOLFOX + bevacizumab, if the patient received one, will not count towards patients' assessments per protocol. Cycle 1 day 1 (C1D1) of atezolizumab or C1D1 of mFOLFOX6/bevacizumab + atezolizumab will correspond to the first day the patient received therapy on trial
-
Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6; alternatively, MSI-H diagnosed by polymerase chain reaction (PCR)-based assessment of microsatellite alterations (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) are eligible
-
Documentation by PET/CT scan, CT scan, or MRI that the patient has measurable metastatic disease per RECIST 1.1
-
No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass
-
Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior randomization)
-
Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)
-
Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)
-
Total bilirubin must be =< 4 x ULN (upper limit of normal) (obtained within 28 days prior randomization); and
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior randomization)
-
Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior randomization)
-
A urine sample tested for proteinuria by either the dipstick method, urinalysis (UA), or a urine protein creatinine (UPC) ratio:
- The dipstick method must indicate 0-1+ protein; if dipstick reading is >= 2+, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
- A urine protein creatinine (UPC) ratio must be < 1.0; if the UPC ratio is >= 1.0 a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours
- Urinalysis must indicate < 30 mg/dl. If urinalysis >= 30 mg/dl, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
-
International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history, regardless of PT/INR results
-
Pregnancy test done within 28 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; administration of atezolizumab or mFOLFOX6/bevacizumab/atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
-
Women of child-bearing potential and men must agree to use adequate contraception methods that result in a failure rate of < 1% per year during the treatment period (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; a woman is considered to be of childbearing potential if she is not postmenopausal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus); examples of contraceptive methods with a failure rate of < 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices; the reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception; men must refrain from donating sperm during this same period
Exclusion Criteria:
-
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
-
Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria
-
Documented New York Heart Association (NYHA) class III or IV congestive heart failure
-
Serious or non-healing wound, skin ulcer, or bone fracture
-
History of inherited bleeding diathesis, gastrointestinal (GI) perforation, significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis or symptomatic peripheral ischemia, transient ischemic attack [TIA], cerebrovascular accident [CVA] or arterial thrombotic event), abdominal fistula, intra-abdominal abscess, or active GI bleeding (with cause not addressed) within 6 months prior to randomization, or other medical condition in the opinion of the treating oncologist that makes the risk of cardiovascular or bleeding complications with bevacizumab use unacceptably high
-
Other malignancies are excluded unless the patient has completed therapy for the malignancy >= 12 months prior to randomization and is considered disease-free; patients with the following cancers are eligible if diagnosed and treated within the past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the skin
-
Known DPD (dihydro pyrimidine dehydrogenase) deficiency
-
Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0)
-
Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization
-
History of grade 2 hemoptysis (defined as 2.5 mL of bright red blood per episode) within 1 month prior to screening
-
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:
- Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization
- No history of severe immune-related adverse effects (CTCAE grade 3 and 4) from anti-CTLA-4
-
Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,
- Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled
- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,
- Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible if polymerase chain reaction (PCR) for hepatits B virus (HBV) ribonucleic acid (RNA) is negative per local guidelines
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA per local guidelines
-
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,
-
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
-
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible
-
Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
-
-
History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active or recently active (within 90 days of randomization) pneumonitis (including drug induced) that required systemic immunosuppressive therapy (i.e. corticosteroids, etc.). History of radiation pneumonitis in the radiation field (fibrosis) is permitted
-
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
-
Patients with known active tuberculosis (TB) are excluded
-
Severe infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
-
Signs or symptoms of infection within 14 days prior to randomization
-
Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
-
The administration of a live, attenuated vaccine within 28 days prior to randomization
-
Pregnant women are excluded from this study because atezolizumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab; these potential risks may also apply to other agents used in this study; (Note: pregnancy testing should be performed within 28 days prior to randomization according to institutional standards for women of childbearing potential)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm I (bevacizumab, mFOLFOX6)
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL) |
Ancillary studies
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo MRI
Andra namn:
Ancillary studies Undergo collection of blood samples
Andra namn:
Given IV
Andra namn:
Undergo CT or CT/PET
Andra namn:
Given IV
Andra namn:
Undergo CT/PET
Andra namn:
|
|
Experimentell: Arm II (atezolizumab)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Andra namn:
Undergo MRI
Andra namn:
Ancillary studies Undergo collection of blood samples
Andra namn:
Given IV
Andra namn:
Undergo CT or CT/PET
Andra namn:
Undergo CT/PET
Andra namn:
|
|
Experimentell: Arm III (atezolizumab, bevacizumab, mFOLFOX6)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo MRI
Andra namn:
Ancillary studies Undergo collection of blood samples
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo CT or CT/PET
Andra namn:
Given IV
Andra namn:
Undergo CT/PET
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression free survival (PFS)
Tidsram: From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
The analysis set is intent-to-treat (ITT). The experimental arms will be compared to the control arm by the log-rank test stratified by BRAF status (V600E mutation or not), metastatic disease: (liver-only, extra-hepatic), and prior adjuvant therapy for colon cancer (yes, no). Hazard ratios and associated confidence intervals from a stratified Cox regression model will also be reported along with estimates of the distributions of time to PFS event by the method of Kaplan and Meier. Sensitivity analyses accounting for 2 or more consecutively missed scheduled tumor imaging scans before progression/death will also be conducted. |
From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PFS-hastighet
Tidsram: Vid 12 månader
|
Vid 12 månader
|
|
|
Overall survival (OS)
Tidsram: The time from randomization to death from any cause, assessed up to 5 years
|
Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
The time from randomization to death from any cause, assessed up to 5 years
|
|
Objective response rate (ORR) (complete response [CR] or partial response [PR])
Tidsram: Up to 5 years
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemotherapy [chemo]) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
Up to 5 years
|
|
Incidence of adverse events
Tidsram: Up to 30 days after last cycle
|
Defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The safety profile will be described by tabulating the maximum observed grade of adverse event for each individual adverse event, for each system organ class, and overall using the Safety population. |
Up to 30 days after last cycle
|
|
Disease control rate (CR + PR + stable disease [SD])
Tidsram: At 12 months
|
Assessed by RECIST 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
At 12 months
|
|
Duration of overall response (CR or PR)
Tidsram: From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed by RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
|
Duration of SD
Tidsram: From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed per RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Severity of fatigue
Tidsram: At 16 weeks
|
Will use the ITT population. Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue questionnaire. Will be compared between the control arm (Chemo-bevacizumab [Bev]) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Physical functioning
Tidsram: At 16 weeks
|
Will use the ITT population. Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire (QLQ)-C30 physical functioning scale. Will be compared between the control arm (Chemo-Bev) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Health utility scores
Tidsram: Up to 5 years
|
Will use the ITT population. Will be measured using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. |
Up to 5 years
|
|
Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G)
Tidsram: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Intratumoral lymphocyte PD-L1+ expression (>= 1 % is positive) by immunohistochemistry (IHC) as a predictive biomarker of efficacy
Tidsram: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy dependent on the number of somatic mutations
Tidsram: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy in tumors with MLH1 silencing
Tidsram: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations
Tidsram: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
Development of progression or relapse to treatment in cfDNA
Tidsram: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Changes in T-cell repertoire diversity as a predictive biomarker of efficacy
Tidsram: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
PFS of patients with high levels of diversity
Tidsram: Up to 5 years
|
Compared to patients with low levels of diversity. Will use the ITT population. |
Up to 5 years
|
|
Change in T-cell diversity
Tidsram: Baseline to first restaging between immunotherapy arms and the standard of care arm
|
Will use the ITT population. |
Baseline to first restaging between immunotherapy arms and the standard of care arm
|
|
Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected
Tidsram: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Caio Max S Rocha Lima, NRG Oncology
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Tarmsjukdomar
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Kolonsjukdomar
- Kolorektala neoplasmer
- Aminosyror, peptider och proteiner
- Proteiner
- Svavelföreningar
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Undersökningstekniker
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Enzymer och koenzymer
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Oorganiska kemikalier
- Koordinationskomplex
- Pyrimidiner
- Kemitekniker, analytiska
- Spektrumanalys
- Formyltetrahydrofolat
- Tetrahydrofolat
- Folinsyra
- Pteriner
- Pteridiner
- Uracil
- Pyrimidinoner
- Koenzymer
- Immunglobulinisotyper
- Sulfider
- Anjoner
- Joner
- Elektrolyter
- Vätesulfid
- Oxaliplatin
- Bevacizumab
- Fluorouracil
- Leucovorin
- Immunoglobulin G
- Provhantering
- Magnetresonansspektroskopi
- Disulfider
- atezolizumab
- dehydroftorafur
Andra studie-ID-nummer
- NCI-2016-01961
- U10CA180868 (U.S.S. NIH-anslag/kontrakt)
- NCI-2016-01961 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- NRG-GI004/S1610
- NRG-GI004 (Annan identifierare: CTEP)
- NRG-GI004 (Annan identifierare: NRG Oncology)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .